top of page
The latest from NuvOx
Search
NuvOx Announces Dosing of 87th Patients in Its RESTORE trial: A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM
Tucson, AZ – September 26, 2025 - NuvOx Therapeutics, Inc. (“NuvOx”) announced that it has dosed 87 patients in its RESTORE trial: A...
Sep 29
NuvOx Announces First Patient Dosed for its EXTEND trials: novEl oXygen ThErapeutic NanO2 for mild respiratory distress in Phase Ib and ARDS in Phase II Trials
Tucson, AZ – June 12, 2025 - NuvOx Therapeutics, Inc. (“NuvOx”) announced that the first patient has been dosed for its EXTEND trials :...
Jun 17
NIH Panel - Commercializing SBIR/STTR Technologies
Featuring Co-Founder and Executive Chairman Dr. Evan Unger As Panelist in Commercializing SBIR/STTR Technologies Discussion at 2025 BIO...
Jun 13
NuvOx Announces Receipt of IND for Study of NanO2 as Cardioprotectant in Acute Myocardial Infarction
NuvOx Announces Receipt of IND for Study of NanO2 as Cardioprotectant in Acute Myocardial Infarction Tucson, AZ – March 4, 2025 - NuvOx...
Mar 17
NuvOx Announces MHRA Approval to Commence Phase IIb Stroke Trial
Tucson, AZ – January 21,2025 - NuvOx Therapeutics, Inc. (“NuvOx”) announced that The Medicines and Healthcare products Regulatory Agency...
Feb 12
bottom of page